DaVita Tops Zacks Estimate – Analyst Blog
Zacks Market Commentaries (November 4th, 2009) Writes:
DaVita Inc. (DVA) reported third quarter net income of $110.9 million or $1.06 per share, which was better than the Zacks Consensus Estimate of 99 cents. The company earned $93.9 million or 89 cents in the comparable quarter of 2008.
Revenues for the quarter came in at $1.57 billion, which reflected an 8.3% increase over the year-ago quarter. According to segments, revenues from the Dialysis and Related Lab Services segment for the quarter came in at $1.49 billion as against $1.38 billion in the prior-year quarter. Other - Ancillary Services and Strategic Initiatives segment generated revenues of $83 million as against $69 million in the year-ago quarter. Highlights of the strong display in the reported quarter included consistent volume growth, stable private pricing and strong cash flows.
Total treatments for the quarter came in at approximately 4.34 million, or 54,927 treatments per day, representing a per ...
Tags for this Post:
Analyst, cent;, DaVita Inc;, dialysis, dialysis services, end stage renal disease, ESRD, Investing Lessons, Pharmaceuticals, Stocks to Watch, USD, Zacks Market Commentaries
Analyst, cent;, DaVita Inc;, dialysis, dialysis services, end stage renal disease, ESRD, Investing Lessons, Pharmaceuticals, Stocks to Watch, USD, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
